Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

Atai Beckley N.V.

CIK 1840904Updated Oct 6, 2026

Name history
ATAI Life Sciences N.V. · through Nov 5, 2025ATAI Life Sciences B.V. · through Jun 21, 2021

No exchange listing on record for this SEC filer. Coverage is drawn from its filings.

Filing activity

SEC EDGAR
Latest filing

15-12G · Dec 31, 2025

50 filings on record · 15-12G, POSASR, 8-K, 424B7, 10-Q, 425.

About the company

AtaiBeckley is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments. It was formed through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited in November 2025. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (buccal film DMT) for TRD and EMP-01 (oral R-MDMA) for social anxiety disorder, which are in Phase 2 clinical development. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create new possibilities in mental health by providing effective, commercially scalable and convenient interventional psychiatry therapies that can integrate seamlessly into healthcare systems.

8-K · 2025-11-12 · 0001140361-25-041546

Company description from the cited filing.

Recent filings

  1. 15-12G filing

    15-12G · 2025-12-31 · 0001140361-25-046932

  2. POSASR filing

    POSASR · 2025-12-31 · 0001140361-25-046929

  3. Other Events

    Items 8.01, 9.01

    8-K · 2025-12-05 · 0001140361-25-044579

  4. 424B7 filing

    424B7 · 2025-12-05 · 0001140361-25-044570

  5. 10-Q filing

    10-Q · 2025-11-12 · 0001193125-25-277583

Show 5 more recent filings
  1. Results of Operations and Financial Condition

    Items 2.02, 9.01

    8-K · 2025-11-12 · 0001140361-25-041546

  2. Other Events

    Items 8.01, 9.01

    8-K · 2025-11-05 · 0001140361-25-040444

  3. 424B7 filing

    424B7 · 2025-11-05 · 0001140361-25-040439

  4. Completion of Acquisition or Disposition of Assets · Unregistered Sales of Equity Securities · Regulation FD Disclosure

    Items 2.01, 3.02, 7.01, 9.01

    8-K · 2025-11-05 · 0001140361-25-040429

  5. Submission of Matters to a Vote of Security Holders

    Items 5.07

    8-K · 2025-11-04 · 0001140361-25-040358

Financials

FY 2024 · USD
Revenue308,000USD · FY 2024
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

Net income-149,269,000USD · FY 2024
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

Operating income-102,691,000USD · FY 2024
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

Diluted EPS-0.93USD per share · FY 2024
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

Some figures are unavailable for this reporting year.

balance sheet · annual statements
Line itemFY 2024FY 2023FY 2022FY 2021
ASSETS
AssetsUSD159,387,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

293,478,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

305,441,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

414,166,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

As of 2021-12-31

Property, Plant and Equipment, NetUSD2,535,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

981,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

928,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

149,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

As of 2021-12-31

GoodwillUSD331,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

———
Intangible Assets, Net (Excluding Goodwill)USD3,246,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

———
Current assets:
Cash and Cash Equivalents, at Carrying ValueUSD17,505,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

45,034,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

190,613,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

362,266,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

As of 2021-12-31

Assets, CurrentUSD80,125,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

185,592,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

287,145,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

375,082,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

As of 2021-12-31

Prepaid Expense and Other Assets, CurrentUSD7,795,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

5,830,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

14,036,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

11,903,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

As of 2021-12-31

Operating Lease, Right-of-Use AssetUSD1,334,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

1,223,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

200,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

—
Other Assets, NoncurrentUSD850,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

2,720,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

3,351,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

7,341,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

As of 2021-12-31

LIABILITIES AND EQUITY
LiabilitiesUSD42,833,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

49,162,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

39,675,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

28,207,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

As of 2021-12-31

Stockholders’ equity:
Common Stock, Value, IssuedUSD18,785,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

18,573,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

18,562,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

18,002,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

As of 2021-12-31

Additional Paid in CapitalUSD816,185,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

794,787,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

774,092,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

725,045,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

As of 2021-12-31

Retained Earnings (Accumulated Deficit)USD-700,207,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

-550,938,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

-510,188,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

-357,803,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

As of 2021-12-31

Accumulated Other Comprehensive Income (Loss), Net of TaxUSD-18,466,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

-19,460,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

-21,702,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

-8,336,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

As of 2021-12-31

Stockholders' Equity Attributable to ParentUSD116,297,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

242,962,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

260,740,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

376,908,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

As of 2021-12-31

Liabilities and EquityUSD159,387,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

293,478,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

305,441,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

414,166,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

As of 2021-12-31

Current liabilities:
Liabilities, CurrentUSD24,951,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

20,120,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

19,897,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

20,935,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

As of 2021-12-31

Operating Lease, Liability, CurrentUSD477,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

275,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

100,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

—
Accounts Payable, CurrentUSD2,616,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

4,589,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

2,399,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

6,004,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

As of 2021-12-31

Operating Lease, Liability, NoncurrentUSD732,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

990,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

100,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

—
Other Liabilities, NoncurrentUSD2,695,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

7,918,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

3,708,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

4,097,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

As of 2021-12-31

Stockholders' Equity Attributable to Noncontrolling InterestUSD257,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

1,354,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

5,026,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

9,051,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

As of 2021-12-31

Additional Financial Items
Accrued Liabilities, CurrentUSD9,847,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

15,256,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

17,306,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

14,829,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

As of 2021-12-31

Long-term DebtUSD14,133,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

15,047,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

14,702,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

—
Long-term Debt, Current MaturitiesUSD6,374,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

0
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

0
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

—
Redeemable Noncontrolling Interest, Equity, Carrying AmountUSD——0
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

0
Source

10-K · 2022-03-30 · 0000950170-22-005013

As of 2021-12-31

Restricted Cash and Investments, CurrentUSD10,000,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

———

Lines labelled “Derived” are calculated from reported figures.

cash flow · annual statements
Line itemFY 2024FY 2023FY 2022FY 2021
Cash flows from operating activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD-150,049,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-43,895,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

-157,417,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-174,244,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, Depletion and AmortizationUSD473,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

319,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

168,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

47,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Share-based Payment Arrangement, Noncash ExpenseUSD25,490,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

32,982,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

42,375,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

63,362,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Changes in operating assets and liabilities:
Increase (Decrease) in Accounts PayableUSD-1,872,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

2,138,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

-3,034,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

2,300,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Deferred Income Tax Expense (Benefit)USD—0
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

5,074,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-5,106,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Net Cash Provided by (Used in) Operating ActivitiesUSD-82,437,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-84,118,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

-104,467,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-63,246,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Cash flows from investing activities:
Net Cash Provided by (Used in) Investing ActivitiesUSD59,172,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-53,295,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

-86,848,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-81,276,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Payments for (Proceeds from) Other Investing ActivitiesUSD———0
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Payments to Acquire Property, Plant, and EquipmentUSD6,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

259,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

773,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

173,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Cash flows from financing activities:
Payments for Repurchase of Common StockUSD———500,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Net Cash Provided by (Used in) Financing ActivitiesUSD5,374,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-8,355,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

20,785,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

409,862,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD-17,529,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-145,578,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

-171,653,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

265,020,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD27,505,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

45,034,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

As of 2023-12-31

190,613,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

As of 2022-12-31

362,266,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

As of 2021-12-31

Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD2,159,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

1,923,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

508,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

—
Additional Financial Items
Amortization of Intangible AssetsUSD200,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

———
DepreciationUSD200,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

———
Equity Method Investment, Realized Gain (Loss) on DisposalUSD——0
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

16,923,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Fair Value, Option, Changes in Fair Value, Gain (Loss)USD3,800,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

5,500,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

0
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-12,346,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Foreign Currency Transaction Gain (Loss), before TaxUSD-1,263,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-894,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

6,902,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

8,481,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Foreign Currency Transaction Gain (Loss), UnrealizedUSD-1,078,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-799,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

4,950,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

11,346,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

General and Administrative ExpenseUSD47,544,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

63,582,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

70,350,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

92,745,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

GoodwillUSD331,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

———
Goodwill, Impairment LossUSD0
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

———
Impairment of Intangible Assets, Finite-livedUSD919,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

———
Income (Loss) from Equity Method InvestmentsUSD-2,000,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-3,593,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

-16,006,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-58,555,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Income Tax Expense (Benefit)USD-356,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

1,016,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

6,229,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-3,989,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

InterestExpenseNonoperatingUSD3,124,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

———
Investment Income, InterestUSD778,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

1,847,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

548,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

205,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Net Income (Loss) Attributable to ParentUSD-149,269,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-40,224,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

-152,385,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-167,808,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Net Income (Loss) Attributable to Noncontrolling InterestUSD-780,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-3,671,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

-5,032,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-6,436,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Net Income (Loss) Available to Common Stockholders, BasicUSD-149,269,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-40,224,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

——
Nonoperating Income (Expense)USD-45,714,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

86,185,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

9,605,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-796,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Operating ExpensesUSD102,999,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

125,785,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

145,020,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

156,181,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Other Nonoperating Income (Expense)USD-484,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-189,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

-1,412,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-293,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Payments of Financing CostsUSD161,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

100,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

1,745,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

—
Proceeds from Issuance of Common StockUSD——0
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

409,884,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD65,560,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

138,983,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

226,834,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

—
Proceeds from Noncontrolling InterestsUSD———0
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Proceeds from Stock Options ExercisedUSD535,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

205,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

2,294,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

935,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Restricted Cash and Investments, CurrentUSD10,000,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

As of 2024-12-31

———
Restructuring CostsUSD2,029,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

3,200,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

——

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemFY 2024FY 2023FY 2022FY 2021
Total RevenueUSD308,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

314,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

233,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

20,376,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Operating Income (Loss)USD-102,691,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-125,471,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

-144,787,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-135,805,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Other Nonoperating Income (Expense)USD-484,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-189,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

-1,412,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-293,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD-148,405,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-39,286,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

-135,182,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-136,601,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Income Tax Expense (Benefit)USD-356,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

1,016,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

6,229,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-3,989,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Net Income (Loss) Attributable to Noncontrolling InterestUSD-780,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-3,671,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

-5,032,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-6,436,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Net Income (Loss) Attributable to ParentUSD-149,269,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-40,224,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

-152,385,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-167,808,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Earnings Per Share, BasicUSD per share-0.93
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-0.25
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

-0.98
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

—
Earnings Per Share, DilutedUSD per share-0.93
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-0.25
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

-0.98
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

—
Weighted Average Number of Shares Outstanding, Basicshares160,159,983
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

158,833,785
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

155,719,585
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

—
Weighted Average Number of Shares Outstanding, Dilutedshares160,159,983
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

158,833,785
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

155,719,585
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

—
Interest Expense (non-operating)USD3,124,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

———
Additional Financial Items
Amortization of Intangible AssetsUSD200,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

———
Current Income Tax Expense (Benefit)USD356,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

1,016,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

1,155,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

1,117,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Fair Value, Option, Changes in Fair Value, Gain (Loss)USD3,800,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

5,500,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

0
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-12,346,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Foreign Currency Transaction Gain (Loss), before TaxUSD-1,263,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-894,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

6,902,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

8,481,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

General and Administrative ExpenseUSD47,544,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

63,582,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

70,350,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

92,745,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Goodwill, Impairment LossUSD0
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

———
Income (Loss) Attributable to Parent, before TaxUSD-148,405,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-39,286,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

-135,182,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-136,601,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD-95,551,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

19,916,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

-55,845,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-89,061,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Income (Loss) from Equity Method InvestmentsUSD-2,000,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-3,593,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

-16,006,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-58,555,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Interest ExpenseUSD—2,656,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

——
Investment Income, InterestUSD778,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

1,847,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

548,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

205,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Labor and Related ExpenseUSD500,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

500,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

500,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

—
Net Income (Loss) Available to Common Stockholders, BasicUSD-149,269,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

-40,224,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

——
Nonoperating Income (Expense)USD-45,714,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

86,185,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

9,605,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

-796,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Operating ExpensesUSD102,999,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

125,785,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

145,020,000
Source

10-K · 2023-03-24 · 0000950170-23-009756

2022-01-01 to 2022-12-31

156,181,000
Source

10-K · 2022-03-30 · 0000950170-22-005013

2021-01-01 to 2021-12-31

Research and Development ExpenseUSD400,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

2,000,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

——
Restructuring CostsUSD2,029,000
Source

10-K · 2025-03-17 · 0000950170-25-040244

2024-01-01 to 2024-12-31

3,200,000
Source

10-K · 2024-03-28 · 0000950170-24-038138

2023-01-01 to 2023-12-31

——

Lines labelled “Derived” are calculated from reported figures.

Filing attachments

ef20058743_ex99-1.htm · 8-K · 2025-11-12

EX-99.1 2 ef20058743_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights AtaiBeckley solidifies position as a global leader in transformative mental health therapies with a short psychedelic duration BPL-003 (mebufotenin benzoate nasal spray) granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for treatment-resistant depression (TRD) Reported positive topline data from the P…

8-K · 2025-11-12 · 0001140361-25-041546

Read attachment ↗
ef20058318_ex99-1.htm · 8-K · 2025-11-05

EX-99.1 2 ef20058318_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies atai Life Sciences’ shareholders voted to approve the strategic combination with Beckley Psytech Limited and the corporate redomiciliation at the Extraordinary General Meeting of Shareholders on November 4, 2025, with approximately 98% of the vot…

8-K · 2025-11-05 · 0001140361-25-040429

Read attachment ↗
ef20057467_ex99-1.htm · 8-K · 2025-10-21

EX-99.1 2 ef20057467_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003 NEW YORK and AMSTERDAM, October 20, 2025 - atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutic…

8-K · 2025-10-21 · 0001140361-25-038748

Read attachment ↗
ef20057374_ex99-1.htm · 8-K · 2025-10-20

EX-99.1 4 ef20057374_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 atai Life Sciences Announces Pricing of Public Offering of Common Shares NEW YORK and AMSTERDAM, October 16, 2025 - atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 23,725,000 common shares, at a price of $5.48 per share. atai has granted the underwr…

8-K · 2025-10-20 · 0001140361-25-038525

Read attachment ↗
ny20057248x2_ex99-1.htm · 8-K · 2025-10-16

EX-99.1 2 ny20057248x2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression Breakthrough Therapy designation recognizes the potential of BPL-003 to deliver substantial improvement over existing therapies for patients with treatment-resistant depression FDA designation follows previously announced Phase 2b topline data which showed…

8-K · 2025-10-16 · 0001140361-25-038319

Read attachment ↗
ef20056757_ex99-1.htm · 8-K · 2025-10-10

EX-99.1 2 ef20056757_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BECKLEY PSYTECH LIMITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) FOR THE SIX MONTHS ENDED June 30, 2025 Beckley Psytech Limited Interim Condensed Consolidated Statement of Comprehensive Loss For the six months ended June 30, 2025 and 2024 (Unaudited) Notes 2025 2024 ─────────────────────────────────────────────────────────…

8-K · 2025-10-10 · 0001140361-25-037941

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.